Correlation Between China Asset and CSPC Innovation

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both China Asset and CSPC Innovation at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining China Asset and CSPC Innovation into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between China Asset Management and CSPC Innovation Pharmaceutical, you can compare the effects of market volatilities on China Asset and CSPC Innovation and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in China Asset with a short position of CSPC Innovation. Check out your portfolio center. Please also check ongoing floating volatility patterns of China Asset and CSPC Innovation.

Diversification Opportunities for China Asset and CSPC Innovation

-0.3
  Correlation Coefficient

Very good diversification

The 3 months correlation between China and CSPC is -0.3. Overlapping area represents the amount of risk that can be diversified away by holding China Asset Management and CSPC Innovation Pharmaceutical in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CSPC Innovation Phar and China Asset is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on China Asset Management are associated (or correlated) with CSPC Innovation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CSPC Innovation Phar has no effect on the direction of China Asset i.e., China Asset and CSPC Innovation go up and down completely randomly.

Pair Corralation between China Asset and CSPC Innovation

Assuming the 90 days trading horizon China Asset is expected to generate 4.24 times less return on investment than CSPC Innovation. But when comparing it to its historical volatility, China Asset Management is 3.58 times less risky than CSPC Innovation. It trades about 0.13 of its potential returns per unit of risk. CSPC Innovation Pharmaceutical is currently generating about 0.15 of returns per unit of risk over similar time horizon. If you would invest  2,610  in CSPC Innovation Pharmaceutical on September 3, 2024 and sell it today you would earn a total of  241.00  from holding CSPC Innovation Pharmaceutical or generate 9.23% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

China Asset Management  vs.  CSPC Innovation Pharmaceutical

 Performance 
       Timeline  
China Asset Management 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days China Asset Management has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, China Asset is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
CSPC Innovation Phar 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in CSPC Innovation Pharmaceutical are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, CSPC Innovation sustained solid returns over the last few months and may actually be approaching a breakup point.

China Asset and CSPC Innovation Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with China Asset and CSPC Innovation

The main advantage of trading using opposite China Asset and CSPC Innovation positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if China Asset position performs unexpectedly, CSPC Innovation can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CSPC Innovation will offset losses from the drop in CSPC Innovation's long position.
The idea behind China Asset Management and CSPC Innovation Pharmaceutical pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Complementary Tools

FinTech Suite
Use AI to screen and filter profitable investment opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm